Development of an Improved Whole Blood Assay for Diagnosis of Latent and Active Tuberculosis Cases
Rupam R. Nashine, Amit R. Nayak, Aliabbas Husain, Gargi D. Mudey, Hatim F. Daginawala, Lokendra Singh, Rajpal S. Kashyap
Journal of Pharmaceutical Research International · pp. 197–209 · Published 27 Jul 2021
10.9734/jpri/2021/v33i38B32115Abstract
Background: Latent TB infection (LTBI) is an infection where the presence of disease causing organism M. tuberculosis is there without any sign and symptoms of the disease hence mostly remains undiagnosed, though Tuberculin skin test (TST) and Interferon Gamma Release Assay (IGRA) were used to diagnose the LTBI. They have their limitations, TST gives major cross-reactivity with BCG vaccine and gives inaccurate results in individuals who have taken BCG and IGRA are very costly and variable sensitivity is repeated in various populations hence the modifications are needed in the IGRA for proper diagnosis of LTBI. Objectives: In the proposed study we aimed to develop an improved whole blood assay towards a diagnosis of latent and active TB infection as an alternative to the Quantiferon QFT assay Methodology: Synthetic antigenic peptides against latency specific antigens will be designed and synthesized. Designed peptides will be screened for LTBI specific cytokine by in-vitro experiments. Development & production of Whole assay using selected peptides evaluation of developed assay through ELISA in clinical samples. Expected Results: Latent specific peptides will be identified and peptide-based whole blood assay for detection and diagnosis of tuberculosis will be developed as an indigenous alternative for the existing QFT assay. Conclusion: An improved whole blood assay will be developed for screening of LTBI in the Indian population.
Cited by 15
Rohini Kakde, S. Gujar, Ashish Bhagat · Journal of Pharmaceutical Negative Results · 2022
Arasha F. Khan, Deepali Patil · Journal of Pharmaceutical Negative Results · 2022
Dipali D. Zade, Vaishnavi Yadav · Journal of Pharmaceutical Negative Results · 2022
Devyani K. Chhadi, Deepali Patil · Journal of Pharmaceutical Negative Results · 2022
Spandan Munjewar, Deepali Patil · Journal of Pharmaceutical Negative Results · 2022
Alfiza Khan, Deepali Patil · Journal of Pharmaceutical Negative Results · 2022
Aishwarya Chaudhari, R. Walke · Journal of Pharmaceutical Negative Results · 2022
Ayushi Mantri, Deepali Patil · Journal of Pharmaceutical Negative Results · 2022
F. Kazi, Deepali Patil · Journal of Pharmaceutical Negative Results · 2022
A. Ambekar, R. Walke · Journal of Pharmaceutical Negative Results · 2022
Related research
- Outcome of Childhood Tuberculosis at a Specialist Hospital in Gusau, Nigeria — shares topic coverage
- Weight Gain as Tuberculosis Treatment Regimen Progresses in Patients Receiving Antituberculosis Therapy — shares topic coverage
- Socio-Demographic and Nutritional Status Correlates in Pulmonary Tuberculosis Patients in Calabar, Nigeria — shares topic coverage
- Diagnostic Accuracy of Ziehl-Neelsen Smear Microscopy in Comparison with GeneXpert in Pulmonary Tuberculosis: A Multi-Center Study in Kandahar Province, Afghanistan — shares topic coverage
- A Short History of the BCG Vaccine — shares topic coverage
Article metrics
Real usage data collected on this platform.
54
Page views
0
PDF downloads
10
Outbound clicks
15
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.